RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerN/A

Registered title, quoted from ClinicalTrials.gov

Postbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Daping Hospital, Army Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorDaping Hospital, Army Medical University陆军军医大学大坪医院ChongqingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07185308, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Patients with histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) classified as stage III-IV according to the 9th TNM edition of IASLC, who are either currently receiving or have completed chemotherapy combined with immunotherapy.

    Inclusion criterion 2

  3. Major surgery within 4 weeks prior to randomization or major surgery planned during the study period.

    Exclusion criterion 4

  4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3 and an estimated life expectancy of ≥ 4 months.

    Inclusion criterion 4

  5. Cachexia attributable to other etiologies (e.g., chronic obstructive pulmonary disease, heart failure, or HIV/AIDS).

    Exclusion criterion 3

  6. Pregnant or lactating women.

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07185308, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥ 18 years, regardless of gender.

-

  • Patients with histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) classified as stage III-IV according to the 9th TNM edition of IASLC, who are either currently receiving or have completed chemotherapy combined with immunotherapy.

-

  • Cachexia was diagnosed according to the international consensus criteria: involuntary weight loss >5 % within 6 months preceding screening, or BMI <20 kg/m² combined with >2 % involuntary weight loss within the same period.

-

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3 and an estimated life expectancy of ≥ 4 months.

-

  • Prior to the first dose of study treatment, adequate organ function must be documented (no blood products, granulocyte-colony-stimulating factors, or thrombopoietic agents within 14 days before randomisation): 1) Absolute neutrophil count ≥ 1.5 × 10\^9/L;2)Platelet count ≥ 100 × 10\^9/L; 3) Haemoglobin > 90 g/L; 4) Serum creatinine < 1.5 × upper limit of normal (ULN) or creatinine clearance (Cockcroft-Gault) > 50 mL/min; 5) Total bilirubin < 1.5 × ULN (< 3 × ULN in Gilbert's syndrome) ;6) AST and ALT < 2.5 × ULN (≤ 5 × ULN if hepatic metastases present); 7) INR and aPTT ≤ 1.5 × ULN unless the participant is on therapeutic anticoagulation; 8) Left-ventricular ejection fraction (LVEF) > 50 %

-

  • Participants must be capable of providing written informed consent and comprehending the potential risks associated with the intervention.

-

  • Participants must demonstrate high adherence to the study protocol.

-

  • Gastrointestinal function score of < 5.

Exclusion Criteria:

  • Current presence of reversible causes of reduced food intake (e.g., oral mucositis or mechanical obstruction).

-

  • Participants who are receiving tube feeding or parenteral nutrition at the time of screening or randomization.

-

  • Cachexia attributable to other etiologies (e.g., chronic obstructive pulmonary disease, heart failure, or HIV/AIDS).

-

  • Major surgery within 4 weeks prior to randomization or major surgery planned during the study period.

-

  • Initiation of systemic corticosteroid therapy within 4 weeks prior to randomization.

-

  • Use of any appetite- or weight-enhancing agent within 30 days before randomisation, including anamorelin, megestrol acetate, cannabinoids, olanzapine, or mirtazapine.

-

  • Use of antibiotics or probiotic-containing medications/foods within 2 weeks prior to randomization.

-

  • Use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight reduction within 30 days prior to randomization.

-

  • Pregnant or lactating women.

-

  • Participants who are unable to understand the study objectives or who do not agree to comply with the study requirements.

-

  • Individuals who lack full legal capacity or whose legal capacity is restricted.

-

  • Any medical condition that could interfere with the interpretation of study results or increase the participant's risk in the opinion of the investigators.

-

  • Participation in any other clinical trial.

-

  • Gastrointestinal function score of ≥ 5.

Quoted from ClinicalTrials.gov, NCT07185308, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07185308, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07185308